Clinical trials: Immune Checkpoint Inhibitors (ICIs)
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
Head and Neck Squamous Cell Carcinoma
The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors
The PRINCESS study is a hypothesis-generating, interventional, open-label, non pharmacological trial designed to characterize the translational and clinical implications of the regular assumptions of inulin on Gut Microbiota…
- Trial name
- PRINCESS (NCT05821751)
- Testing
- inulin, Pembrolizumab, Nivolumab
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs).
- Trial name
- NCT06119347
- Testing
- AntiVEGF, ICIs
- Where
- China
- Volunteers
- 1,581 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Malignant Tumor, Immunotherapy
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed…
- Conditions
- Malignant Tumor, Immunotherapy, Artificial Intelligence
- Trial name
- NCT05862259
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xinqiao Hospital of Chongqing
Lung Cancer, Immune Checkpoint Inhibitor
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance…
- Conditions
- Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy
- Trial name
- NCT05754203
- Testing
- Super-hyperfractionation Pulse Radiotherapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Xinqiao Hospital of Chongqing
Radiotherapy, Immune Checkpoint Inhibitors (ICIs)
Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study
Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly.
- Trial name
- NCT07665736
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan University
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital